INVESTMENT IN JOINT VENTURE	6 Months Ended
Jun. 30, 2025
Equity Method Investments and Joint Ventures [Abstract]
INVESTMENT IN JOINT VENTURE	INVESTMENT IN JOINT VENTURE Prior to the JV Sale, the Company, through one of its wholly-owned subsidiaries, had a 50% interest of the joint venture entity, RE Ventures I, LLC, a limited liability company (“REV-I”). For the three months ended June 30, 2025 and 2024, the Company funded $0.5 million and $0.8 million, respectively, associated with the Company's commitment and its share of REV-I development costs. For both the six months ended June 30, 2025 and 2024, the Company funded $1.5 million associated with the Company's commitment and its share of REV-I development costs. The Company did not provide any additional financial support outside of capital contributions to REV-I during the three and six months ended June 30, 2025 and 2024. However, in connection with the joint venture, the Company provided certain scientific and finance and accounting related support which was reimbursed by REV-I to the Company and is included in other income on the condensed consolidated statements of operations and comprehensive loss. For the three and six months ended June 30, 2025 and 2024, the Company recorded $0.1 million and $0.3 million, respectively, related to such support. While the Company held a 50% interest in the joint venture as of June 30, 2025, based on management’s analysis, the Company was not the primary beneficiary of REV-I and accordingly, the entity was not consolidated in the Company's condensed consolidated financial statements. For the three and six months ended June 30, 2025, the Company recorded its allocable share of REV-I's losses which totaled $0.3 million and $0.9 million, respectively, and for the three and six ended June 30, 2024, the Company recorded its allocable share of REV-I's losses which totaled and $0.5 million and $1.2 million, respectively. These losses were recorded as a loss on investment in joint venture within the condensed consolidated statements of operations and comprehensive loss. After recognition of its share of losses for the period, the carrying value and maximum exposure to risk of the REV-I investment as of June 30, 2025 was $0.6 million, which was recorded in investment in joint venture in the Company's condensed consolidated balance sheets. There was no carrying value remaining of the REV-I investment as of December 31, 2024. For further details on the JV Sale, please refer to Note 12.

INVESTMENT IN JOINT VENTURE

6 Months Ended

Jun. 30, 2025

Equity Method Investments and Joint Ventures [Abstract]

Prior to the JV Sale, the Company, through one of its wholly-owned subsidiaries, had a 50% interest of the joint venture entity, RE Ventures I, LLC, a limited liability company (“REV-I”). For the three months ended June 30, 2025 and 2024, the Company funded $0.5 million and $0.8 million, respectively, associated with the Company's commitment and its share of REV-I development costs. For both the six months ended June 30, 2025 and 2024, the Company funded $1.5 million associated with the Company's commitment and its share of REV-I development costs. The Company did not provide any additional financial support outside of capital contributions to REV-I during the three and six months ended June 30, 2025 and 2024. However, in connection with the joint venture, the Company provided certain scientific and finance and accounting related support which was reimbursed by REV-I to the Company and is included in other income on the condensed consolidated statements of operations and comprehensive loss. For the three and six months ended June 30, 2025 and 2024, the Company recorded $0.1 million and $0.3 million, respectively, related to such support. While the Company held a 50% interest in the joint venture as of June 30, 2025, based on management’s analysis, the Company was not the primary beneficiary of REV-I and accordingly, the entity was not consolidated in the Company's condensed consolidated financial statements.

For the three and six months ended June 30, 2025, the Company recorded its allocable share of REV-I's losses which totaled $0.3 million and $0.9 million, respectively, and for the three and six ended June 30, 2024, the Company recorded its allocable share of REV-I's losses which totaled and $0.5 million and $1.2 million, respectively. These losses were recorded as a loss on investment in joint venture within the condensed consolidated statements of operations and comprehensive loss. After recognition of its share of losses for the period, the carrying value and maximum exposure to risk of the REV-I investment as of June 30, 2025 was $0.6

million, which was recorded in investment in joint venture in the Company's condensed consolidated balance sheets. There was no carrying value remaining of the REV-I investment as of December 31, 2024.

For further details on the JV Sale, please refer to Note 12.